Is nivolumab given to patients on a weekly or biweekly basis?

Standard Dosing Schedule for Nivolumab

Nivolumab (Opdivo) is typically given every 2 weeks (biweekly) or every 4 weeks for most approved indications, not weekly. The exact schedule depends on the cancer type, combination therapy, and patient factors like body weight.[1]

How Dosing Varies by Cancer Type

• Melanoma or non-small cell lung cancer (monotherapy): 240 mg every 2 weeks or 480 mg every 4 weeks via IV infusion over 30 minutes.[1]
  
• Renal cell carcinoma or classical Hodgkin lymphoma: Often 240 mg every 2 weeks.[1]
  
• With ipilimumab (e.g., melanoma, MSI-H/dMMR cancers): Nivolumab 1 mg/kg every 3 weeks, alternating with ipilimumab—not weekly or strictly biweekly.[1]
  
• With chemotherapy (e.g., NSCLC): 360 mg every 3 weeks.[1]
  Doses are calculated by body weight (e.g., 3 mg/kg) in some cases, but flat dosing is common for adults.[1]
  
  

Why Not Weekly?

Weekly dosing is rare and not standard; nivolumab's half-life of about 25 days supports less frequent administration to maintain efficacy while minimizing infusion burden. Clinical trials like CheckMate established 2- or 4-week intervals as optimal.[2]

What Happens with Dose Adjustments or Missed Doses?

Adjust for toxicity (e.g., hold or discontinue for severe immune-related side effects like pneumonitis). If a dose is missed, give as soon as possible within the cycle, then resume schedule—do not double up.[1] Pediatric dosing (for some cancers) uses 3 mg/kg every 2 weeks.[1]

Patient and Practical Considerations

Infusions take 30 minutes; biweekly suits outpatient settings. Fixed doses reduce errors vs. weight-based. Check prescribing info or oncologist for personalized regimens, as off-label use might differ.[1]

[1]: Nivolumab Prescribing Information (FDA/BMS)
[2]: CheckMate Trial Data (NEJM)